» Articles » PMID: 31504944

Health-related Quality of Life in Systemic Sclerosis Before and After Autologous Haematopoietic Stem Cell Transplant-a Systematic Review

Overview
Specialty Rheumatology
Date 2019 Sep 11
PMID 31504944
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: In severe rapidly progressive SSc, autologous haematopoietic stem cell transplantation (AHSCT) allows significant improvements in overall and event-free survival. We undertook this study to identify, appraise and synthesize the evidence on health-related quality of life (HRQoL) before and after AHSCT for SSc.

Methods: We performed a systematic review of the literature, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, in PubMed and ScienceDirect from database inception to 1 February 2019. All articles with original HRQoL data were selected.

Results: The search identified 1080 articles, of which 8 were selected: 3 unblinded randomized controlled trials [American Scleroderma Stem Cell versus Immune Suppression Trial (ASSIST), Autologous Stem Cell Transplantation International Scleroderma, Scleroderma: Cyclophosphamide or Transplantation), 3 uncontrolled phase I or II trials and 2 cohort studies. HRQoL data from 289 SSc patients treated with AHSCT and 125 treated with intravenous CYC as a comparator with median 1.25-4.5 years follow-up were included. HRQoL was evaluated with the HAQ Disability Index (HAQ-DI; 275 patients), the 36-item Short Form Health Survey (SF-36; 249 patients) and the European Quality of Life 5-Dimensions questionnaire (EQ-5D; 138 patients). The quality of the studies was moderate to low. AHSCT was associated with significant improvement in the HAQ-DI (P = 0.02-<0.001), SF-36 Physical Component Summary score (P = 0.02-<0.0001) and EQ-5D index-based utility score (P < 0.001). The SF-36 Mental Component Summary score improved in the ASSIST (n = 19) and one small retrospective cohort (n = 30 patients, P = 0.005) but did not improve significantly in 2 randomized controlled trials (n = 200 patients, P = 0.1-0.91).

Conclusion: AHSCT in severe SSc patients is associated with significant and durable improvement in physical HRQoL.

Citing Articles

Psychological impact of autologous hematopoietic stem cell transplantation in systemic sclerosis patients and influence of resilience.

Schmalzing M, Gernert M, Frohlich M, Henes J, Schwindl N, Zerhusen L Front Immunol. 2024; 15:1436639.

PMID: 39512343 PMC: 11540678. DOI: 10.3389/fimmu.2024.1436639.


Stem cell-based therapy for systemic sclerosis.

Moghaddam M, Mousavi M, Ghotloo S Rheumatol Adv Pract. 2023; 7(3):rkad101.

PMID: 38075180 PMC: 10701795. DOI: 10.1093/rap/rkad101.


Hematopoietic Cell Transplantation for Systemic Sclerosis-A Review.

Levin D, Osman M, Durand C, Kim H, Hemmati I, Jamani K Cells. 2022; 11(23).

PMID: 36497169 PMC: 9739132. DOI: 10.3390/cells11233912.


Improving outcomes in scleroderma: recent progress of cell-based therapies.

Khanna D, Krieger N, Sullivan K Rheumatology (Oxford). 2022; 62(6):2060-2069.

PMID: 36355455 PMC: 10234204. DOI: 10.1093/rheumatology/keac628.


State of the art and future directions in assessing the quality of life in rare and complex connective tissue and musculoskeletal diseases.

Trieste L, Cannizzo S, Palla I, Triulzi I, Turchetti G Front Med (Lausanne). 2022; 9:986218.

PMID: 36213631 PMC: 9537631. DOI: 10.3389/fmed.2022.986218.